Phaseline

Companies › Xintian Pharmaceutical

Xintian Pharmaceutical: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 4; Metabolic and endocrine; next expected readout Jul 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JiRui® Prunella oral liquid
Herbal preparation with purported anti-inflammatory and immunomodulatory effects
–Phase 4Thyroid NoduleJul 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06423235JiRui® Prunella oral liquidPhase 4Thyroid NoduleMetabolic and endocrineJul 2028

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

BrightGene New Bio-Medical Technology(Wuxi) Co.Ltd. Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics Orphalan Lumos Pharma Neuvosyn Laboratories

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.